Onkológia 2/2025
Modern treatment of Philadelphia-positive acute lymphoblastic leukemia: benefit of tyrosine kinase inhibitors
Philadelphia positive acute lymphoblastic leukemia has undergone major advances in the last decade. A disease that has been described as a very high risk leukemia with very poor survival and an unfavourable prognosis is becoming a disease that is likely to be treatable in the near future, according to the latest clinical trials, with a chemo-free regimen, by a combination of tyrosine kinase inhibitors and a bispecific CD19/CD3 antibody.
Keywords: acute lymphoblastic leukemia, blinatumomab, ponatinib, stem cell transplantation, minimal residual disease